**SUPPLEMENTARY TABLE 1A. Patient Demographics of Studies Comparing CKD to non-CKD Patients**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Studies | Groups | Definition | Sample Size (N) | Age (years; mean ± SD) | Maxim-um Follow-up | MaleN (%) | CADN (%) | DMN (%) | COPDN (%) | TIA/ CVAN (%) | DyslipidemiaN (%) | Tobacco useN (%) | HypertensionN (%) | CHFN (%) |
| Bakken et al. (14) | **CKD**  | GFR ≤60 ml/min/1.73 m2 | 290 | 69 ± 12 | 5 years | 186 (64) | 151 (52) | 180 (62) | NA | 41 (14) | 197 (68) | 26 (9) | 252 (87) | 107 (37) |
| **Non-CKD**  | GFR >60 ml/min/1.73 m2 | 345 | 66 ± 14 | 5 years | 221 (64) | 138 (40) | 141 (41) | NA | 41 (12) | 200 (58) | 62 (18) | 273 (79) | 62 (18) |
| Kim HO et al. (17) | **CKD**  | GFR ≤60 ml/min/1.73 m2 and not on dialysis | 272 | 70.8 ± 9.0 | 9.5 years | 232 (85) | 159 (59) | 194 (71) | NA | 65 (24) | 108 (40) | 64 (24) | 238 (88) | 39 (14) |
| **Non-CKD**  | GFR >60 ml/min/1.73 m2 | 2,467 | 68.5 ± 9.5 | 9.5 years | 2,057 (83) | 1,341 (54) | 1,292 (52) | NA | 326 (13) | 981 (40) | 843 (34) | 1,731 (70) | 108 (4) |
| Lantis et al (20) | **CKD** | Mean creatinine level > 1.2 mg/dL and not on dialysis | 37 | 67 | 4 years | 23 (61) | 19 (50) | 28 (76) | NA | 6 (17) | NA | 9 (24) | NA | 6 (17) |
| **Non-CKD** | Creatinine level ≤ 1.2 mg/dL | 481 | 69 | 4 years | 265 (55) | 241 (50) | 212 (44) | NA | 58 (12) | NA | 178 (37) | NA | 58 (12) |
| Ogawa et al. (24) | **CKD** | GFR ≤60 ml/min/1.73 m2 | 321 | 72.1 ± 8.8 | 2 years | 218 (67.9) | NA | 222 (69.2) | 19 (5.9) | NA | 182 (56.7) | NA | 275 (85.7) | NA |
| **Non-CKD**  | GFR >60 ml/min/1.73 m2 | 584 | 74.2 ± 8.2 | 2 years | 418 (71.6) | NA | 310 (53.1) | 54 (9.2) | NA | 368 (63.0) | NA | 498 (85.3) | NA |
| Willenberg et al. (26)  | **CKD ≥4 and ESRD** | GFR <30 ml/min/1.73 m2 and/or dialysis dependent | 22 | 72.5 ± 10.6 | 1 year | 13 (59.1) | 17 (77.3) | 14 (63.6) | NA | 0 (0) | 12 (54.5) | 12 (54.5) | 17 (77.3) | NA |
| **Normal function and CKD ≤2** | GFR ≥60 ml/min/1.73 m2 | 104 | 75.6 ± 10.6 | 1 year | 73 (70.2) | 68 (65.4) | 62 (59.6) | NA | 25 (24.0) | 51 (49.0 | 53 (51.0) | 78 (75.0) | NA |
| Xie et al. (27)  | **CKD** | GFR ≤60 ml/min/1.73 m2 | 201 | 69.7 ± 9 | 6 years | 199 (99) | 56 (27.9) | 135 (67.2) | 67 (33.3) | NA | 186 (92.5) | 162 (80.6) | 199 (99) | 72 (35.8) |
| **Non-CKD**  | GFR >60 ml/min/1.73 m2 | 554 | 63.4 ± 8.3 | 6 years | 548 (98.9) | 142 (25.6) | 253 (45.7) | 165 (29.8) | NA | 501 (90.4) | 491 (88.6) | 495 (89.4) | 126 (22.7) |

‡CAD – Coronary Artery Disease; §CHF – Congestive heart failure; ǁCKD – Chronic kidney disease; \*\*COPD – Chronic obstructive pulmonary disease; ǁǁEF – Ejection fraction of left ventricle; \*\*\* GFR – Glomerular filtration rate;

**SUPPLEMENTARY TABLE 1B. Patient Demographics of Studies Comparing ESRD to non-ESRD Patients**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Studies | Group Comparison | Definition | Sample Size(N) | Age (years; mean ± SD) | Maximum Follow-up | MaleN (%) | CADN (%) | DMN (%) | COPDN (%) | TIA/ CVA | DyslipidemiaN (%) | Tobacco useN (%) | HypertensionN (%) | CHFN (%) | EF (%) |
| Baer Bositis et al. (13) | **ESRD** | Dialysis dependent | 171 | 61 ± 12 | 5 years | 97 (57) | 72 (42) | 150 (88) | NA | 41 (24) | 127 (74) | 26 (15) | 168 (98) | 67 (39) | NA |
| **Non-ESRD**  | Non-dialysis dependent | 658 | 55 ± 13 | 5 years | 368 (56) | 263 (40) | 533 (81) | NA | 145 (22) | 454 (69) | 86 (13) | 632 (96) | 237 (36) | NA |
| Davies et al. (15) | **ESRD**  | Dialysis dependent | 78 | 66 ± 12 | 3 years | 44 (57) | 33 (43) | 68 (88) | NA | 19 (24) | 51 (65) | 15 (20) | 76 (98) | 12 (16) | NA |
| **Non-ESRD**  | Non-dialysis dependent | 164 | 50 ± 13 | 3 years | 82 (50) | 65 (40) | 126 (77) | NA | 36 (22) | 96 (59) | 21 (13) | 152 (93) | 64 (39) | NA |
| Kawarada et al(16).  | **ESRD**  | Dialysis dependent | 49 | 65 ± 8 | 5 years | 38 (78) | 35 (71) | 35 (71) | NA | 8 (16) | 10 (20) | 36 (74) | 41 (84) | 21 (43) | NA |
| **Non-ESRD**  | Non-dialysis dependent | 43 | 73 ± 8 | 5 years | 30 (70) | 23 (54) | 36 (84) | NA | 18 (42) | 18 (42) | 28 (65) | 32 (74) | 9 (21) | NA |
| Kumada et al. 2008(19) | **ESRD**  | Dialysis dependent | 118 | 64 ± 10 | 5 years | 68 (58) | 60 (51) | 85 (72) | NA | 11 (9) | 42 (36) | 36 (31) | 98 (83) | NA | NA |
| **Non-ESRD**  | Mean GFR of 76.5 ± 17.5 ml/min/1.73 m2 | 108 | 69 ± 9 | 5 years | 76 (70) | 34 (32) | 57 (53) | NA | 8 (7) | 50 (46) | 55 (51) | 90 (83) | NA | NA |
| Kumada et al. 2015 (18) | **ESRD**  | Dialysis depedent | 177 | 67 ± 9 | 5 years | 132 (75) | 72 (41) | 103 (58) | NA | 18 (10) | 31 (18) | 33 (19) | 96 (54) | NA | NA |
| **Non-ESRD**  | Non-dialysis dependent | 49 | 72 ± 9 | 5 years | 30 (61) | 18 (37) | 24 (49) | NA | 2 (4) | 8 (16) | 7 (14) | 28 (57) | NA | NA |
| Lantis et al.(20) | **ESRD**  | Dialysis dependent | 60 | 63 | 4 years | 28 (46) | 38 (64) | 50 (83) | NA | 7 (12) | NA | 5 (8) | NA | 13 (22) | NA |
| **Non-ESRD** | creatinine level ≤ 1.2 mg/dL | 481 | 69 | 4 years | 265 (55) | 241 (50) | 212 (44) | NA | 58 (12) | NA | 178 (37) | NA | 58 (12) | NA |
| Meyer et al. (21) | **ESRD**  | GFR <15 ml/min/1.73 m2 and on dialysis | 102 | 73 (64-78) (median; IQR) | 11 days (5-13 days) (median; IQR) | 81 (79) | 67 (66) | 62 (61) | NA | 14 (14) | NA | 14 (14) | NA | NA | NA |
| **Non-ESRD** | GFR ≥60 ml/min/1.73 m2 | 674 | 72 (63-78) (median; IQR) | 11 days (11-12 days) (median; IQR) | 456 (68) | 255 (38) | 292 (43) | NA | 79 (12) | NA | 174 (26) | NA | NA | NA |
| Nakano et al. 2013(23) | **ESRD**  | Dialysis dependent | 242 | 67.8 ± 9.7 | 5 years | 188 (78) | 146 (60) | 167 (69) | 6 (3) | 88 (36) | 55 (23) | 62 (26) | 201 (83) | NA | 56.4 ± 15.0 |
| **Non-ESRD**  | Non-dialysis dependent | 164 | 74.5 ± 11.3 | 5 years | 87 (53) | 64 (39) | 113 (69) | 5 (3) | 40 (24) | 62 (38) | 59 (36) | 113 (69) | NA | 60.9 ± 12.7 |
| Nakano et al. 2015(22) | **ESRD**  | Dialysis dependent | 670 | 69.1 ± 9.4 | 5 years | 516 (77) | 362 (54.0) | 501 (74.8) | 59 (8.8) | 169 (25.2) | 219 (52.0) | 239 (35.7) | 500 (74.6) | NA | 57.1 ± 14.2 |
| **Non-ESRD**  | Non-dialysis dependent | 421 | 75.3 ± 10.6 | 5 years | 242 (57.4) | 181 (43.0) | 299 (71.0) | 34 (8.1) | 88 (20.9) | 233 (34.8) | 145 (34.4) | 303 (72.0) | NA | 60.9 ± 12.3 |
| Rao et al.(25)  | **ESRD**  | Dialysis dependent | 1,623 | 66.0 ± 10.7 | 1 month | 1,019 (63) | 76 (5) | 1,034 (64) | 248 (15) | 115 (7) | NA | 419 (26) | 1,457 (90) | 127 (8) | NA |
| **Non-ESRD**  | Non-dialysis dependent | 33,318 | 66.7 ± 11.0 | 1 month | 22,190 (64) | 1166 (4) | 12,228 (37) | 5,131 (15) | 2,166 (7) | NA | 15,526 (47) | 27,187 (82) | 766 (2) | NA |
| Yammamoto et al.(28) | **ESRD**  | Dialysis dependent | 46 | 63.4 ± 12.1 | 5 years | 37 (80.4) | 41 (73) | 48 (86) | 18 (32) | 13 (23) | 19 (34) | 45 (80) | 52 (93) | 3 (5) | 61.3 ± 11.2 |
| **Non-ESRD**  | Non-dialysis dependent | 73 | 73.8 ± 8.9 | 5 years | 52 (71.2) | 40 (51) | 46 (59) | 37 (48) | 30 (39) | 35 (45) | 62 (80) | 65 (83) | 11 (14) | 65.8 ± 10.2 |

‡CAD – Coronary Artery Disease; §CHF – Congestive heart failure; ǁCKD – Chronic kidney disease; \*\*COPD – Chronic obstructive pulmonary disease; ǁǁEF – Ejection fraction of left ventricle; \*\*\* GFR – Glomerular filtration rate;

**SUPPLEMENTARY TABLE 2. Risk of bias assessment using the modified New Castle Ottawa Scale (Refer to Supplementary Appendix 1 below)**

|  |
| --- |
| **Risk of Bias** |
| **Study** | **A1\*** | **A2\*** | **A3\*** | **A\*** | **B1\*** | **B2\*** | **C1\*** | **C2\*** | **C3\*** | **D1\*** |
| **Baer Bositis et al (13)** |  |  |  |  |  |  |  |  |  |  |
| **Bakken et al (14)** |  |  |  |  |  |  |  |  |  |  |
| **Davies et al (15)** |  |  |  |  |  |  |  |  |  |  |
| **Kawarada et al (16)** |  |  |  |  |  |  |  |  |  |  |
| **Kim Ho et al (17)** |  |  |  |  |  |  |  |  |  |  |
| **Kumada et al 2015 (18)** |  |  |  |  |  |  |  |  |  |  |
| **Kumada et al. 2008 (19)** |  |  |  |  |  |  |  |  |  |  |
| **Lantis et al (20)** |  |  |  |  |  |  |  |  |  |  |
| **Meyer et al (21)** |  |  |  |  |  |  |  |  |  |  |
| **Nakano et al. 2015 (22)** |  |  |  |  |  |  |  |  |  |  |
| **Nakano et al. 2013 (23)** |  |  |  |  |  |  |  |  |  |  |
| **Ogawa et al (24)** |  |  |  |  |  |  |  |  |  |  |
| **Rao et al (25)** |  |  |  |  |  |  |  |  |  |  |
| **Willenberg et al (26)** |  |  |  |  |  |  |  |  |  |  |
| **Xie JK et al (27)** |  |  |  |  |  |  |  |  |  |  |
| **Yamamoto et al (28)** |  |  |  |  |  |  |  |  |  |  |

***Good Quality****: 3 or 4 green boxes in selection domain AND 1 or 2 green boxes in comparability domain AND 2 or 3 green boxes in outcome/exposure domain*

***Fair quality****: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain*

***Poor quality****: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain*

**\*Supplementary Appendix 1 for Supplementary Table 1.**

**Risk of bias assessment tool**

The risk of bias tool was developed by the authors for the purposes of this review and is based on the Newcastle–Ottawa scale. It is structured around three domains which represent the three main sources of bias in observational studies. Each domain comprises a number of items or “signaling questions” responses to which allow reviewers to assign a risk of bias category as follows: red for moderate-to-high risk of bias, green for low risk of bias and amber where there is sufficient information to make a judgement.

Some signaling questions were dropped from the risk of bias assessment of cross-sectional studies, as they were not appropriate (e.g. item B3).

|  |
| --- |
| **DOMAIN A: Selection of participants (selection bias)** |
| **A1** | **Is the study (source or sample) population appropriate and representative of the population of interest (i.e. the general population)?**Yes (green), No (red), Not clear (amber)  |
|  |  |
| **A2** | **Is the selection of unexposed (mechanical valves) drawn from the same community as exposed cohort?**Yes (green), No (red), Not clear (amber) |
|  |  |
|  |  |
| **A3** | **Is the ascertainment of exposure (surgery) clear?**Yes (green), No (red) |
|  |  |
|  |  |
| **A4**  | **Is the outcome present in study subjects at the start of the study?** Yes (green), No (red), Not clear (amber) |
| **DOMAIN B: COMPARABILITY**  |
| **B1** | **Did the study identify and appropriately adjust for potential confounders that might influence the findings?**Yes (green), No (red), Not clear (amber) |
|  |  |
| **B2** | **Is the sample size adequate and is there sufficient power to detect a meaningful difference in the outcome of interest?**Yes (green), No (red), Not clear (amber) |
|  |  |
| **DOMAIN C: OUTCOME**  |
| **C1** | **Is the methodology of the outcome assessment explicitly stated and is ascertainment/ measurement of the main outcome(s) adequate and appropriate (i.e. how is infective endocarditis defined/established; is it objective)?**Yes (green), No (red), Not clear (amber) |
|  |  |
| **C2** | **Was follow-up long enough for the outcomes of interest to occur?**Yes (green), No (red), Not clear (amber) |
|  |  |
| **C3** | **Are there missing data and if so did the study handle the missingness in an appropriate manner?**Yes (green), No (red), Not clear (amber) |
|  |  |
| **DOMAIN 4: Other**  |
| **D1** | **Anything else of concern in terms of potential sources of bias (study specific)**No (green), Yes (red), Not clear (amber) |
|  |  |

**SUPPLEMENTARY TABLE 3A. Indication and Lesion Characteristics of Studies Comparing CKD to non-CKD**

| Studies | Groups | ABI | Claudication (RC 1-3) | CLIN (%) | Rest Pain (RC 4)N (%) | Ulcer / Gangrene (RC 5-6)N (%) | Lesion Length (mm) | AortoiliacN (%) | FemoropoplitealN (%) | Infra-poplitealN (%) | Balloon AngioplastyN (%) | Stenting | Endovascular Therapy | Open Repair / Bypass Graft |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bakken et al. (14) | **CKD**  | NA | 142 (49) | 148 (51) | 61 (21) | 87 (30) | NA | 6 | 100 | 9 | Yes | Yes (+/-) | Yes | No |
| **Non-CKD**  | NA | 231 (67) | 114 (33) | 45 (13) | 69 (20) | NA | 12 | 100 | 6 | Yes | Yes (+/-) | Yes | No |
| Kim HO et al. (17) | **CKD**  | NA | 214 limbs (62) | 132 limbs (38) | 27 limbs (8) | 105 limbs (30) | 110.8 ± 93.2 | NA | NA | NA | Yes | Yes (+/-) | Yes | No |
| **Non-CKD**  | NA | 2,325 limbs (73) | 877 limbs (27) | 249 limbs (8) | 628 limbs (20) | 111.3 ± 98.8 | NA | NA | NA | Yes | Yes (+/-) | Yes | No |
| Lantis et al (20) | **CKD** | NA | 10 | NA | NA | 68 | NA | NA | NA | NA | No | No | No | Yes (SVG) |
| **Non-CKD** | NA | 23 | NA | NA | 48 | NA | NA | NA | NA | No | No | No | Yes (SVG) |
| Ogawa et al. (24) | **CKD** | NA | 238 (74.1) | NA | 49 (15.3) | 71 (22.1) | 145.8 ± 93.1 | NA | 100 | NA | Yes | Yes (DES) | Yes | No |
| **Non-CKD**  | NA | 554 (94.9) | NA | 56 (9.6) | 41 (7.0) | 147.3 ± 98.2 | NA | 100 | NA | Yes | Yes (DES) | Yes | No |
| Willenberg et al. (26)  | **CKD ≥4 and ESRD** | 0.38 ± 0.32 | NA | 22 (100) | NA | NA | NA | 4.2 | 62.5 | 66.7 | Yes | No | Yes | No |
| **Normal function and CKD ≤2** | 0.37 ± 0.26 | NA | 104 (100) | NA | NA | NA | 16.7 | 65.7 | 59.3 | Yes | Yes (+/-) | Yes | No |
| Xie et al. (27)  | **CKD** | NA | 151 (75.1) | 50 (49.9) | NA | NA | NA | NA | NA | NA | Yes | NA | Yes | No |
| **Non-CKD**  | NA | 449 (81) | 105 (19) | NA | NA | NA | NA | NA | NA | Yes | NA | Yes | No |

\*ABI – Ankle-brachial index; ǁCKD – Chronic kidney disease; #CLI – Critical limb ischemia; \*\*COPD – Chronic obstructive pulmonary disease; \*\*\* GFR – Glomerular filtration rate; \*\*\*\*RC – Rutherford Classification;

†††††Type of stent used was at the discretion of the interventionalist. The exact percentages on type stent including bare-metal, drug-eluting, or covered stent not specified.

‡‡‡‡‡Open repair refers to common femoral, proximal superficial femoral, or profunda endarterectomy and patch angioplasty.

**SUPPLEMENTARY TABLE 3B. Indication and Lesion Characteristics of Studies Comparing CKD to non-CKD**

| Studies | Group Comparison | ABI | Claudication (RC 1-3) | Critical Limb Ischemia | Rest Pain (RC 4) | Ulcer / Gangrene (RC 5-6) | Lesion Length (mm) | Aortoiliac | Femoropopliteal | Infra-popliteal | Balloon Angioplasty | Stenting | Endovascular Therapy | Open Repair / Bypass Graft |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baer Bositis et al. (13) | **ESRD**  | NA | 0 (0) | 171 (100) | 171 (100) | 0 (0) | NA | NA | NA | 100 | Yes | No | Yes | No |
| **Non-ESRD**  | NA | 0 (0) | 658 (100) | 658 (100) | 0 (0) | NA | NA | NA | 100 | Yes | No | Yes | No |
| Davies et al. (15) | **ESRD**  | NA | 0 (0) | 78 (100) | 0 (0) | 78 (100) | NA | NA | NA | 100 | Yes | Yes (+/-) | Yes | Yes (+/-) (SVG) |
| **Non-ESRD**  | NA | 0 (0) | 164 (100) | 0 (0) | 164 (100) | NA | NA | NA | 100 | Yes | Yes (+/-) | Yes | Yes (+/-) (SVG) |
| Kawarada et al(16).  | **ESRD**  | NA | 0 (0) | 49 (100) | NA | NA | NA | NA | NA | 100 | Yes | Yes (BMS) | Yes | No |
| **Non-ESRD**  | NA | 0 (0) | 43 (100) | NA | NA | NA | NA | NA | 100 | Yes | Yes (BMS) | Yes | No |
| Kumada et al. 2008(19) | **ESRD**  | 0.61 ± 0.20 | 42 (36) | NA | 40 (34) | 36 (31) | NA | 32 | 68 | 0 | Yes | Yes (+/-) | Yes | No |
| **Non-ESRD**  | 0.63 ± 0.21 | 51 (47) | NA | 34 (32) | 23 (21) | NA | 54 | 46 | 0 | Yes | Yes (+/-) | Yes | No |
| Kumada et al. 2015 (18) | **ESRD**  | 0.65 ± 0.37 | 0 (0) | NA | 11 (6) | 166 (94) | NA | 0 | 20 | 80 | No | No | No | Yes (SVG) |
| **Non-ESRD**  | 0.59 ± 0.29 | 0 (0) | NA | 9 (18) | 40 (82) | NA | 0 | 15 | 85 | No | No | No | Yes (SVG) |
| Lantis et al.(20) | **ESRD**  | NA | 0 | NA | 15 | 85 | NA | NA | NA | NA | No | No | No | Yes (SVG) |
| **Non-ESRD** | NA | 23 | NA | NA | 48 | NA | NA | NA | NA | No | No | No | Yes (SVG) |
| Meyer et al. (21) | **ESRD**  | NA | 0 (0) | 102 (100) | 68 (67) (RC4-5) | 34 (33) (RC6) | NA | NA | NA | NA | Yes | NA | Yes | Yes (NS) |
| **Non-ESRD** | NA | 0 (0) | 674 (100) | 527 (78) (RC4-5) | 147 (22) (RC6) | NA | NA | NA | NA | Yes | NA | Yes | Yes (NS) |
| Nakano et al. 2013(23) | **ESRD**  | 0.57 ± 0.26 | 0 (0) | 283 limbs (100) | 48 limbs (17) | 235 limbs (83) | 171.9 ± 91.1 | 0 | 0 | 100 | Yes | No | Yes | No |
| **Non-ESRD**  | 0.59 ± 0.22 | 0 (0) | 182 limbs (100) | 48 limbs (26) | 134 limbs (74) | 167.0 ± 93.1 | 0 | 0 | 100 | Yes | No | Yes | No |
| Nakano et al. 2015(22) | **ESRD**  | 0.57 ± 0.24 | 0 (0) | 830 (100) | 165 (19.9) | 665 (80.1) | 199.9 ± 96.7 | NA | NA | 100 | Yes | No | Yes | No |
| **Non-ESRD**  | 0.59 ± 0.21 | 0 (0) | 480 (100) | 141 (29.4) | 339 (70.6) | 182.3 ± 98.9 | NA | NA | 100 | Yes | No | Yes | No |
| Rao et al.(25)  | **ESRD**  | NA | NA | 807 (50) | NA | NA | NA | NA | NA | NA | No | No | No | Yes (SVG/PG) |
| **Non-ESRD**  | NA | NA | 11,028 (33) | NA | NA | NA | NA | NA | NA | No | No | No | Yes (SVG/PG) |
| Yammamoto et al.(28) | **ESRD**  | NA | 4 (8.9) | NA | 42 (91.1) | NA | NA | 23.2 | 80.3 | NA | Yes | NA | Yes | Yes (SVG/PG) |
| **Non-ESRD**  | NA | 21 (28.2) | NA |  52 (71.8) | NA | NA | 38.4 | 80.8 | NA | Yes | NA | Yes | Yes (SVG/PG) |

\*ABI – Ankle-brachial index; ǁCKD – Chronic kidney disease; #CLI – Critical limb ischemia; \*\*COPD – Chronic obstructive pulmonary disease; \*\*\* GFR – Glomerular filtration rate; \*\*\*\*RC – Rutherford Classification;

†††††Type of stent used was at the discretion of the interventionalist. The exact percentages on type stent including bare-metal, drug-eluting, or covered stent not specified.

‡‡‡‡‡Open repair refers to common femoral, proximal superficial femoral, or profunda endarterectomy and patch angioplasty.